Vascular device developer Conor Medsystems of Menlo Park, CA, presented acute and follow-up data from its Paclitaxel In-Stent Controlled Elution Study (PISCES) trial at the 2004 Paris Course on Revascularization (PCR) this week in Paris.
The multicenter dose optimization study involves 191 patients in 10 sites across seven countries, according to the company. It compares the safety and performance of six different formulations of paclitaxel for reducing restenosis in the treatment of native coronary artery lesions.
At four-month follow-up, all six formulations were determined to be safe, with a subacute thrombosis rate of 0.5% and no death from discharge to follow-up, the company said.
Conor reported that two of the groups with slower-release formulations had demonstrated good outcomes, and that the remaining four groups with faster-release kinetics had less efficacy with respect to angiographic and intravascular ultrasound (IVUS) endpoints.
By AuntMinnie.com staff writersMay 26, 2004
Related Reading
Conor Medsystems completes paclitaxel stent trial enrollment, March 25, 2004
Copyright © 2004 AuntMinnie.com
